Cargando…

Alteration of the gut microbiota and metabolite phenylacetylglutamine in patients with severe chronic heart failure

Chronic Heart Failure (CHF) is the end result of nearly all cardiovascular disease and is the leading cause of deaths worldwide. Studies have demonstrated that intestinal flora has a close relationship with the development of Cardiovascular Disease (CVD) and plays a vital role in the disease evoluti...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Zhendong, Cai, Bin, Sun, Yanzhuan, Deng, Haiyan, Wang, Hongwei, Qiao, Zengyong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9871785/
https://www.ncbi.nlm.nih.gov/pubmed/36704458
http://dx.doi.org/10.3389/fcvm.2022.1076806
_version_ 1784877258000826368
author Zhang, Zhendong
Cai, Bin
Sun, Yanzhuan
Deng, Haiyan
Wang, Hongwei
Qiao, Zengyong
author_facet Zhang, Zhendong
Cai, Bin
Sun, Yanzhuan
Deng, Haiyan
Wang, Hongwei
Qiao, Zengyong
author_sort Zhang, Zhendong
collection PubMed
description Chronic Heart Failure (CHF) is the end result of nearly all cardiovascular disease and is the leading cause of deaths worldwide. Studies have demonstrated that intestinal flora has a close relationship with the development of Cardiovascular Disease (CVD) and plays a vital role in the disease evolution process. Phenylacetylglutamine (PAGln) a metabolite of the intestinal flora, is one of the common chronic kidney disease toxins. Its concentrations in plasma were higher in patients with major adverse cardiovascular events (MACE) however, its variation in patients with various degrees of CHF has rarely been reported. Therefore, we collected stool and plasma samples from 22 healthy controls, 29 patients with NYHA Class III and 29 patients with NYHA Class IV CHF (NYHA stands for New York Heart Association) from the Department of Cardiology of Shanghai Fengxian District Central Hospital. Next, we analyzed these samples by performing bacterial 16S ribosomal RNA gene sequencing and liquid chromatography tandem mass spectrometry. The result shows: The Chao 1 index was significantly lower in both NYHA class III and NYHA class IV than it was in the control group. The beta diversity was substantially dissimilar across the three groups. The linear discriminant analysis effect size analysis (LEfSe) showed that the bacterial species with the largest differences were Lachnospiraceae in control group, Enterobacteriaceae in NYHA class III, and Escherichia in NYHA class IV. The concentration of PAGln was significantly different between CHF and control groups and increased with the severity of heart failure. Finally, the correlation analysis represented that Parabacteroides and Bacteroides were negatively correlated to brain natriuretic peptide (BNP) and PAGln; Romboutsia and Blautia adversely associated with PAGln; Klebsiella was positively interrelated with BNP; Escherichia-Shigella was positively correlated with PAGln and BNP; Alistipes was contrasted with BNP; and Parabacteroides was negatively correlated with the left ventricular end-diastolic diameter (LVEDD). This study presented that the intestinal flora and its metabolite PAGln were altered with different grades of CHF and illustrated the effects of the gut flora and its metabolite on CHF.
format Online
Article
Text
id pubmed-9871785
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-98717852023-01-25 Alteration of the gut microbiota and metabolite phenylacetylglutamine in patients with severe chronic heart failure Zhang, Zhendong Cai, Bin Sun, Yanzhuan Deng, Haiyan Wang, Hongwei Qiao, Zengyong Front Cardiovasc Med Cardiovascular Medicine Chronic Heart Failure (CHF) is the end result of nearly all cardiovascular disease and is the leading cause of deaths worldwide. Studies have demonstrated that intestinal flora has a close relationship with the development of Cardiovascular Disease (CVD) and plays a vital role in the disease evolution process. Phenylacetylglutamine (PAGln) a metabolite of the intestinal flora, is one of the common chronic kidney disease toxins. Its concentrations in plasma were higher in patients with major adverse cardiovascular events (MACE) however, its variation in patients with various degrees of CHF has rarely been reported. Therefore, we collected stool and plasma samples from 22 healthy controls, 29 patients with NYHA Class III and 29 patients with NYHA Class IV CHF (NYHA stands for New York Heart Association) from the Department of Cardiology of Shanghai Fengxian District Central Hospital. Next, we analyzed these samples by performing bacterial 16S ribosomal RNA gene sequencing and liquid chromatography tandem mass spectrometry. The result shows: The Chao 1 index was significantly lower in both NYHA class III and NYHA class IV than it was in the control group. The beta diversity was substantially dissimilar across the three groups. The linear discriminant analysis effect size analysis (LEfSe) showed that the bacterial species with the largest differences were Lachnospiraceae in control group, Enterobacteriaceae in NYHA class III, and Escherichia in NYHA class IV. The concentration of PAGln was significantly different between CHF and control groups and increased with the severity of heart failure. Finally, the correlation analysis represented that Parabacteroides and Bacteroides were negatively correlated to brain natriuretic peptide (BNP) and PAGln; Romboutsia and Blautia adversely associated with PAGln; Klebsiella was positively interrelated with BNP; Escherichia-Shigella was positively correlated with PAGln and BNP; Alistipes was contrasted with BNP; and Parabacteroides was negatively correlated with the left ventricular end-diastolic diameter (LVEDD). This study presented that the intestinal flora and its metabolite PAGln were altered with different grades of CHF and illustrated the effects of the gut flora and its metabolite on CHF. Frontiers Media S.A. 2023-01-10 /pmc/articles/PMC9871785/ /pubmed/36704458 http://dx.doi.org/10.3389/fcvm.2022.1076806 Text en Copyright © 2023 Zhang, Cai, Sun, Deng, Wang and Qiao. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Cardiovascular Medicine
Zhang, Zhendong
Cai, Bin
Sun, Yanzhuan
Deng, Haiyan
Wang, Hongwei
Qiao, Zengyong
Alteration of the gut microbiota and metabolite phenylacetylglutamine in patients with severe chronic heart failure
title Alteration of the gut microbiota and metabolite phenylacetylglutamine in patients with severe chronic heart failure
title_full Alteration of the gut microbiota and metabolite phenylacetylglutamine in patients with severe chronic heart failure
title_fullStr Alteration of the gut microbiota and metabolite phenylacetylglutamine in patients with severe chronic heart failure
title_full_unstemmed Alteration of the gut microbiota and metabolite phenylacetylglutamine in patients with severe chronic heart failure
title_short Alteration of the gut microbiota and metabolite phenylacetylglutamine in patients with severe chronic heart failure
title_sort alteration of the gut microbiota and metabolite phenylacetylglutamine in patients with severe chronic heart failure
topic Cardiovascular Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9871785/
https://www.ncbi.nlm.nih.gov/pubmed/36704458
http://dx.doi.org/10.3389/fcvm.2022.1076806
work_keys_str_mv AT zhangzhendong alterationofthegutmicrobiotaandmetabolitephenylacetylglutamineinpatientswithseverechronicheartfailure
AT caibin alterationofthegutmicrobiotaandmetabolitephenylacetylglutamineinpatientswithseverechronicheartfailure
AT sunyanzhuan alterationofthegutmicrobiotaandmetabolitephenylacetylglutamineinpatientswithseverechronicheartfailure
AT denghaiyan alterationofthegutmicrobiotaandmetabolitephenylacetylglutamineinpatientswithseverechronicheartfailure
AT wanghongwei alterationofthegutmicrobiotaandmetabolitephenylacetylglutamineinpatientswithseverechronicheartfailure
AT qiaozengyong alterationofthegutmicrobiotaandmetabolitephenylacetylglutamineinpatientswithseverechronicheartfailure